{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:55Z","timestamp":1793118835434,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The approved combination of Tixagevimab\/Cilgavimab has been shown to decrease the rate of symptomatic SARS-CoV-2 infection in patients at increased risk of inadequate response to vaccination. However, Tixagevimab\/Cilgavimab was tested in a few studies that included patients with hematological malignancies, even if this population has shown an increased risk of unfavorable outcomes following infection (with high rates of hospitalization, intensive care unit admission, and mortality) and poor significant immunization following vaccines. We performed a real-life prospective cohort study to evaluate the rate of SARS-CoV-2 infection following pre-exposure prophylaxis with Tixagevimab\/Cilgavimab in anti-spike seronegative patients compared to a cohort of seropositive patients who were observed or received a fourth vaccine dose. We recruited 103 patients with a mean age of 67 years: 35 (34%) received Tixagevimab\/Cilgavimab and were followed from March 17, 2022, until November 15, 2022. After a median follow-up of 4.24 months, the 3-month cumulative incidence of infection was 20% versus 12% in the Tixagevimab\/Cilgavimab and observation\/vaccine groups respectively (HR 1.57; 95% CI: 0.65-3.56; p = 0.34). In this study, we report our experience with Tixagevimab\/Cilgavimab and a tailored approach to SARS-CoV-2 infection prevention in patients with hematological malignancies during the SARS-CoV-2 omicron surge.<\/jats:p>","DOI":"10.3389\/fonc.2023.1212752","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T22:20:45Z","timestamp":1687558845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Tixagevimab\/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Francesco","family":"Angotzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Berno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Bonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Branca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Adele","family":"Cavaretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Forlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Gianesello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Gurrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Imbergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Lessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Maroccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mazzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pezone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pravato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ruocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Scapinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Zoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01333-0","article-title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European research initiative on CLL","volume":"15","author":"Antic","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2020.269878","article-title":"Immunologic characterization of COVID-19 patients with hematological cancer","volume":"106","author":"Maia","year":"2021","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0191","article-title":"Preexisting and post\u2013covid-19 immune responses to sars-cov-2 in patients with cancer","volume":"11","author":"Bilich","year":"2021","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","article-title":"Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients","volume":"39","author":"Abdul-Jawad","year":"2021","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/HON.2872","article-title":"Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection","volume":"39","author":"Candoni","year":"2021","journal-title":"Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/AJH.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016815","article-title":"Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination","volume":"140","author":"Lisa","year":"2022","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014124","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA","volume":"139","author":"Pagano","year":"2022","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26626ff.ffhal-03791162","article-title":"Outcome of infection with omicron SARS-CoV -2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report","volume":"97","author":"Blennow","year":"2022","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjh.18823","article-title":"COVID-19 infection in patients with haematological malignancies: a single-centre survey in the latest omicron wave in China","author":"Zhu","year":"2023","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (tixagevimab-cilgavimab) against omicron SARS-CoV-2 in patients with hematologic malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0023","article-title":"Evaluation of the automated LIAISON\u00aeSARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies","volume":"59","author":"Bonelli","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/JCLA.23921","article-title":"Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls","volume":"35","author":"Jung","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00733-21","article-title":"Serological assays for assessing postvaccination SARS-CoV-2 antibody response","volume":"9","author":"Mahmoud","year":"2021","journal-title":"Microbiol Spectr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM-2021-0313","article-title":"Analytical and clinical performances of a SARS-CoV-2 s-RBD IgG assay: comparison with neutralization titers","volume":"59","author":"Padoan","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.14740\/jh1062","article-title":"Real-world effectiveness of tixagevimab and cilgavimab (Evusheld) in patients with hematological malignancies","volume":"11","author":"Ocon","year":"2022","journal-title":"J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2022018283","article-title":"Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with b-cell malignancies","volume":"141","author":"Davis","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13045-022-01387-0","article-title":"Pre-exposure prophylaxis with tixagevimab\/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the omicron wave: a multicentric retrospective study of SFGM-TC","volume":"15","author":"Jondreville","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18701","article-title":"Pre-exposure prophylaxis with tixagevimab\/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents","volume":"201","author":"Mauro","year":"2023","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01894-1","article-title":"Tixagevimab\/cilgavimab for omicron SARS-CoV-2 infection in patients with haematologic diseases","volume":"58","author":"Otiniano","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transpl"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1654.e1","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac625","article-title":"Association between AZD7442 (Tixagevimab-cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality","volume":"76","author":"Kertes","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/v14102278","article-title":"SARS-CoV-2 pre-exposure prophylaxis with sotrovimab and Tixagevimab\/Cilgavimab in immunocompromised patients-a single-center experience","volume":"14","author":"Totschnig","year":"2022","journal-title":"Viruses"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.07.008","article-title":"COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders","volume":"102","author":"Kaminski","year":"2022","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14040","article-title":"Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients","author":"Ordaya","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/diseases10040118","article-title":"Efficacy and safety of Tixagevimab\/Cilgavimab to prevent COVID-19 (Pre-exposure prophylaxis): a systematic review and meta-analysis","volume":"10","author":"Alhumaid","year":"2022","journal-title":"Diseases"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2420","article-title":"Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: a systematic review and meta-analysis","volume":"33","author":"Soeroto","year":"2023","journal-title":"Rev Med Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add5446","article-title":"An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion","volume":"7","author":"Luo","year":"2022","journal-title":"Sci Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2011623","article-title":"A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses","volume":"1","author":"Pengfei","year":"2022","journal-title":"Emerging Microbes Infections"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1212752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T22:20:48Z","timestamp":1687558848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1212752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":42,"alternative-id":["10.3389\/fonc.2023.1212752"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1212752","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1212752"}}